IQVIA Holdings/$IQV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IQVIA Holdings
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Ticker
$IQV
Sector
Primary listing
NYSE
Employees
90,000
Headquarters
Website
IQVIA Holdings Metrics
BasicAdvanced
$32B
26.97
$6.92
1.32
-
Price and volume
Market cap
$32B
Beta
1.32
52-week high
$243.65
52-week low
$134.65
Average daily volume
1.2M
Financial strength
Current ratio
0.838
Quick ratio
0.739
Long term debt to equity
248.652
Total debt to equity
272.122
Interest coverage (TTM)
3.30%
Profitability
EBITDA (TTM)
2,923
Gross margin (TTM)
34.25%
Net profit margin (TTM)
7.88%
Operating margin (TTM)
14.48%
Effective tax rate (TTM)
19.20%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
5.16%
Return on equity (TTM)
19.79%
Valuation
Price to earnings (TTM)
26.968
Price to revenue (TTM)
2.107
Price to book
5.49
Price to tangible book (TTM)
-2.2
Price to free cash flow (TTM)
16.454
Free cash flow yield (TTM)
6.08%
Free cash flow per share (TTM)
11.346
Growth
Revenue change (TTM)
3.60%
Earnings per share change (TTM)
-10.20%
3-year revenue growth (CAGR)
3.56%
10-year revenue growth (CAGR)
14.02%
3-year earnings per share growth (CAGR)
5.01%
10-year earnings per share growth (CAGR)
9.67%
What the Analysts think about IQVIA Holdings
Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.
Bulls say / Bears say
IQVIA’s Q1 2025 adjusted EPS of $2.70 and revenue of $3.83 billion exceeded Wall Street expectations of $2.63 and $3.77 billion, respectively, leading to a 2.7% increase in the stock pre-market and highlighting strong performance in its core services. (Reuters)
IQVIA raised its full-year 2025 revenue guidance to $16.0 billion–$16.4 billion, above its previous outlook of $15.73 billion–$16.13 billion, taking advantage of favorable currency moves and reflecting confidence in continued growth. (Reuters)
Contract research organizations posted better-than-expected Q2 earnings, with IQVIA reporting positive indicators of stabilizing biopharma demand that could persist into 2026, suggesting a more favorable industry environment. (Reuters)
Analysts warn that demand for clinical trials has not fully recovered, so growth in IQVIA’s core R&D Solutions segment remains muted despite a broader recovery in the sector. (Reuters)
IQVIA’s net leverage ratio was 3.40x trailing twelve-month Adjusted EBITDA as of March 31, 2025, which may limit its financial flexibility for future investments. (IQVIA Q1 2025 Press Release)
Ongoing geopolitical risks, including U.S.-China trade tensions, continue to pose threats to IQVIA’s global clinical trial supply chain, introducing uncertainty to its international operations. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
IQVIA Holdings Financial Performance
Revenues and expenses
IQVIA Holdings Earnings Performance
Company profitability
IQVIA Holdings News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IQVIA Holdings stock?
IQVIA Holdings (IQV) has a market cap of $32B as of September 18, 2025.
What is the P/E ratio for IQVIA Holdings stock?
The price to earnings (P/E) ratio for IQVIA Holdings (IQV) stock is 26.97 as of September 18, 2025.
Does IQVIA Holdings stock pay dividends?
No, IQVIA Holdings (IQV) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next IQVIA Holdings dividend payment date?
IQVIA Holdings (IQV) stock does not pay dividends to its shareholders.
What is the beta indicator for IQVIA Holdings?
IQVIA Holdings (IQV) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.